https://www.biospace.com/esmo ESMO en-US Wed, 28 Oct 2026 00:48:02 GMT https://www.biospace.com/press-releases/signatera-genome-with-phased-and-structural-variants-highlighted-in-esmo-presidential-symposium-supporting-the-critical-role-of-mrd-guided-treatment-in-bladder-cancer Wed, 28 Oct 2026 00:48:02 GMT https://www.biospace.com/press-releases/signatera-genome-with-phased-and-structural-variants-highlighted-in-esmo-presidential-symposium-supporting-the-critical-role-of-mrd-guided-treatment-in-bladder-cancer https://www.biospace.com/press-releases/alpheus-presents-data-on-serial-ldh-kinetics-as-a-potential-blood-based-biomarker-in-glioblastoma Wed, 28 Oct 2026 00:47:30 GMT https://www.biospace.com/press-releases/alpheus-presents-data-on-serial-ldh-kinetics-as-a-potential-blood-based-biomarker-in-glioblastoma https://www.biospace.com/press-releases/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102 Wed, 28 Oct 2026 00:10:40 GMT https://www.biospace.com/press-releases/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102 https://www.biospace.com/press-releases/calidi-biotherapeutics-presented-new-cld-401-data-and-in-situ-tce-platform-advances-at-the-esmo-congress-2026-including-highlighting-the-potential-of-its-redtail-gene-medicine-platform-to-turn-tumors-into-localized-tce-biofactories Tue, 27 Oct 2026 14:28:40 GMT https://www.biospace.com/press-releases/calidi-biotherapeutics-presented-new-cld-401-data-and-in-situ-tce-platform-advances-at-the-esmo-congress-2026-including-highlighting-the-potential-of-its-redtail-gene-medicine-platform-to-turn-tumors-into-localized-tce-biofactories https://www.biospace.com/press-releases/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial-cancer Tue, 27 Oct 2026 01:10:15 GMT https://www.biospace.com/press-releases/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial-cancer https://www.biospace.com/press-releases/chidamide-plus-nivolumab-shows-potential-as-new-standard-of-care-in-advanced-melanoma-reducing-disease-progression-risk-by-27-in-global-phase-3-trial Tue, 27 Oct 2026 01:06:43 GMT https://www.biospace.com/press-releases/chidamide-plus-nivolumab-shows-potential-as-new-standard-of-care-in-advanced-melanoma-reducing-disease-progression-risk-by-27-in-global-phase-3-trial https://www.biospace.com/press-releases/riboscience-presents-phase-1a-b-overall-survival-data-for-enpp1-inhibitor-rbs2418-as-monotherapy-and-in-combination-therapy-in-advanced-solid-tumors-and-late-line-crc Tue, 27 Oct 2026 00:47:33 GMT https://www.biospace.com/press-releases/riboscience-presents-phase-1a-b-overall-survival-data-for-enpp1-inhibitor-rbs2418-as-monotherapy-and-in-combination-therapy-in-advanced-solid-tumors-and-late-line-crc https://www.biospace.com/press-releases/incyte-highlights-new-data-advancing-its-gastrointestinal-cancer-portfolio-at-esmo-2026 Mon, 26 Oct 2026 14:56:29 GMT https://www.biospace.com/press-releases/incyte-highlights-new-data-advancing-its-gastrointestinal-cancer-portfolio-at-esmo-2026 https://www.biospace.com/press-releases/hummingbird-diagnostics-showcases-new-data-utilizing-blood-based-small-rna-for-lung-cancer-treatment-monitoring-at-esmo-congress-2026 Mon, 26 Oct 2026 14:55:19 GMT https://www.biospace.com/press-releases/hummingbird-diagnostics-showcases-new-data-utilizing-blood-based-small-rna-for-lung-cancer-treatment-monitoring-at-esmo-congress-2026 https://www.biospace.com/press-releases/iambic-presents-updated-iam1363-clinical-data-at-esmo-2026-showing-durable-responses-with-a-favorable-tolerability-profile-in-heavily-pretreated-participants-with-her2-driven-cancers Mon, 26 Oct 2026 14:48:06 GMT https://www.biospace.com/press-releases/iambic-presents-updated-iam1363-clinical-data-at-esmo-2026-showing-durable-responses-with-a-favorable-tolerability-profile-in-heavily-pretreated-participants-with-her2-driven-cancers https://www.biospace.com/press-releases/light-chain-bioscience-novimmune-sa-long-term-follow-up-of-ni-1801-in-platinum-resistant-ovarian-cancer-shows-durable-survival-benefit-at-24-months Mon, 26 Oct 2026 14:41:33 GMT https://www.biospace.com/press-releases/light-chain-bioscience-novimmune-sa-long-term-follow-up-of-ni-1801-in-platinum-resistant-ovarian-cancer-shows-durable-survival-benefit-at-24-months https://www.biospace.com/press-releases/aulos-biosciences-imneskibart-with-avelumab-delivers-exceptional-progression-free-survival-in-checkpoint-inhibitor-refractory-adenocarcinoma-non-small-cell-lung-cancer Mon, 26 Oct 2026 14:40:37 GMT https://www.biospace.com/press-releases/aulos-biosciences-imneskibart-with-avelumab-delivers-exceptional-progression-free-survival-in-checkpoint-inhibitor-refractory-adenocarcinoma-non-small-cell-lung-cancer https://www.biospace.com/press-releases/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026 Mon, 26 Oct 2026 14:37:05 GMT https://www.biospace.com/press-releases/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026 https://www.biospace.com/press-releases/new-canadian-real-world-evidence-at-esmo-2026-highlights-integration-of-cldn18-2-testing-and-targeted-treatment-in-clinical-practice Mon, 26 Oct 2026 14:33:32 GMT https://www.biospace.com/press-releases/new-canadian-real-world-evidence-at-esmo-2026-highlights-integration-of-cldn18-2-testing-and-targeted-treatment-in-clinical-practice https://www.biospace.com/press-releases/insilico-medicine-reports-40-orr-at-130-mg-for-pan-tead-inhibitor-ism6331-designed-using-generative-ai-in-heavily-pretreated-mesothelioma-at-esmo-2026 Mon, 26 Oct 2026 14:28:32 GMT https://www.biospace.com/press-releases/insilico-medicine-reports-40-orr-at-130-mg-for-pan-tead-inhibitor-ism6331-designed-using-generative-ai-in-heavily-pretreated-mesothelioma-at-esmo-2026 https://www.biospace.com/press-releases/cytodyn-presents-updated-leronlimab-data-in-metastatic-colorectal-cancer-at-esmo-congress-2026 Mon, 26 Oct 2026 14:15:45 GMT https://www.biospace.com/press-releases/cytodyn-presents-updated-leronlimab-data-in-metastatic-colorectal-cancer-at-esmo-congress-2026 https://www.biospace.com/press-releases/novastra-therapeutics-reports-encouraging-first-clinical-data-for-its-novel-xirt-oap-cancer-immune-therapy-at-esmo-congress-2026 Mon, 26 Oct 2026 13:59:35 GMT https://www.biospace.com/press-releases/novastra-therapeutics-reports-encouraging-first-clinical-data-for-its-novel-xirt-oap-cancer-immune-therapy-at-esmo-congress-2026 https://www.biospace.com/press-releases/transcode-therapeutics-presents-phase-1a-clinical-data-for-ttx-mc138-at-esmo-congress-2026 Mon, 26 Oct 2026 13:48:25 GMT https://www.biospace.com/press-releases/transcode-therapeutics-presents-phase-1a-clinical-data-for-ttx-mc138-at-esmo-congress-2026 https://www.biospace.com/press-releases/immuneering-presents-design-and-methodology-of-ongoing-phase-3-mapkeeper-301-trial-at-esmo-congress-2026 Mon, 26 Oct 2026 13:46:05 GMT https://www.biospace.com/press-releases/immuneering-presents-design-and-methodology-of-ongoing-phase-3-mapkeeper-301-trial-at-esmo-congress-2026 https://www.biospace.com/press-releases/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoson-at-esmo-2026 Mon, 26 Oct 2026 13:41:38 GMT https://www.biospace.com/press-releases/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoson-at-esmo-2026